摘要
近20年,在世界卫生组织(WHO)的推动下,先后有20余种新药或再利用药物进入临床试验,针对多重耐药结核病,WHO推荐了包含新药贝达喹啉和普托马尼/德拉马尼组成的方案。国内应用正起步,本文就这2类新药的历史背景、作用机制、药物代谢特点和临床应用等内容进行综述讨论,以促进临床医生对新药的正确应用。
Under the promotion of WHO,more than 20 new compounds and repurposed drugs have undergone clinical or preclinical studies in the last two decades.The new multidrug-resistant-TB treatment regimens are promoted by the WHO.The two types of new drugs,such as bedaquiline and pretomanid/delamanid,are the core of the new regimens.This review covered the development history,mechanisms,pharmacokinetics,and clinical data of these new drugs to help develop a clinically applicable understanding.
作者
王心静
安慧茹
Wang Xinjing;An Huiru(Tuberculosis Department,The Eighth Medical Center of PLA General Hospital,Beijing 100091)
出处
《中国抗生素杂志》
CAS
CSCD
北大核心
2024年第10期1131-1137,共7页
Chinese Journal of Antibiotics
